Cell Based Assays Global Market Size, Share Report, Rising Trends, Growing Demand and Business Opportunities and Forecast 2024-2033

The Cell Based Assays Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Cell Based Assays Market:
https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

According to The Business Research Company’s Cell Based Assays Global Market Report 2024, The cell based assays market size has grown strongly in recent years. It will grow from $24.61 billion in 2023 to $26.9 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to emergence of hts techniques, integration of automation, utilization of biomarker detection, adoption of microfluidics, introduction of gene editing tools.

The cell based assays market size is expected to see rapid growth in the next few years. It will grow to $41.86 billion in 2028 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to integration of ai and machine learning, shift in regulatory landscape, demand for high-content screening, advancements in disease modeling, focus on precision medicine. Major trends in the forecast period include high-throughput screening (hts), 3d cell cultures, organ-on-a-chip technology, crispr/cas9 technology, advancements in imaging techniques.

Research with cell-based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of investigational new drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to a report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures which is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell-based assays enable scientists to extract more information about the cellular response and help make informed decisions during drug discovery, and further driving the growth of the cell-based array market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2546&type=smp

The cell based assays market covered in this report is segmented –
1) By Product & Service: Consumables, Instruments, Services, Software
2) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Other Technologies
3) By Application: Drug Discovery, Basic Research, Adme Studies, Predictive Toxicology, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Government Research Institutes, Contract Research Organizations (CRO), Other End Users

Sub-segements
By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems
By Consumables: Reagents And Media, Cells And Cell Lines, Probes And Labels

Researchers are inclining toward early-phase predictive toxicity testing that prevents late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase the screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stages. These advances will make clinical testing easy and reduce the cost of operation.

The cell based assays market report table of contents includes:
1. Executive Summary